Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 6; p. 1973
Main Authors Jaramillo, Sonia, Krisam, Johannes, Le Cornet, Lucian, Kratzmann, Markus, Baumann, Lukas, Eissymont, Olga, Crysandt, Martina, Görner, Martin, Kayser, Sabine, Krause, Stefan, Schliemann, Christoph, Gaska, Tobias, Kaufmann, Martin, Chemnitz, Jens, Schaich, Markus, Hoellein, Alexander, Platzbecker, Uwe, Kieser, Meinhard, Müller-Tidow, Carsten, Schlenk, Richard F
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.06.2024
Subjects
Adult
Aged
Aminoglycosides - administration & dosage
Aminoglycosides - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Benzimidazoles
Double-Blind Method
Female
Gemtuzumab - administration & dosage
Gemtuzumab - therapeutic use
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Male
Middle Aged
Phenylurea Compounds
Remission Induction
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Correspondence-3
content type line 23
ObjectType-Undefined-4
ISSN:1592-8721
0390-6078
1592-8721
DOI:10.3324/haematol.2023.284346